Paper No. \_\_\_\_ Filed: June 5, 2017

## UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA, INC. and AKORN INC.,<sup>1</sup>
Petitioners,

v.

ALLERGAN, INC. Patent Owner.

\_\_\_\_\_

Case IPR2016-01127 (US 8,685,930 B2) Case IPR2016-01128 (US 8,629,111 B2) Case IPR2016-01129 (US 8,624,556 B2) Case IPR2016-01130 (US 8,633,162 B2) Case IPR2016-01131 (US 8,648,048 B2) Case IPR2016-01132 (US 9,248,191 B2)

PETITIONER'S NOTICE OF DEPOSITION OF JOHN D. SHEPPARD, M.D., M.S.Sc.

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017 - 00596, IPR2017 -00579 and IPR2017-00598, IPR2017 -00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017 -00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The wordfor-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).



Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc., by

and through its attorneys, will conduct examination by deposition of John D.

Sheppard, M.D., M.M.Sc. Dr. Sheppard's deposition will take place commencing

at 5:00PM (local time) on June 20, 2017, continuing day-to-day if necessary, at the

Holiday Inn Virginia Beach – Norfolk Hotel & Conference Center, 5655

Greenwich Road, Virginia Beach, VA 23462, or at another location mutually

agreeable to the parties. The deposition will be taken before a Notary Public or

other officer authorized by law to administer oaths and will be recorded using

stenographic means. The arrangement for the reporter will be made by counsel for

Petitioner.

Respectfully submitted,

Dated: June 5, 2017

/ Steven W. Parmelee / Steven W. Parmelee

Reg. No. 31,990



## CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioner's Notice of Deposition of John D. Sheppard, M.D., M.M.Sc., on this 5th day of June, 2017, on the Patent Owner at the correspondence address of the Patent Owner as follows:

Dorothy P. Whelan

Michael Kane

Susan Morrison Colletti

Robert M. Oakes

Fish & Richardson P.C.

3200 RBC Plaza

60 South Sixth Street

Minneapolis, MN 55402

Email: IPR13351-0008IP1@fr.com

Email: IPR13351-0008IP2@fr.com

Email: IPR13351-0008IP3@fr.com

Email: IPR13351-0008IP4@fr.com

Email: IPR13351-0008IP5@fr.com

Email: IPR13351-0008IP6@fr.com

Email: PTABInbound@fr.com

and on the remaining petitioners as follows:

Gary Speier

Mark Schuman

CARLSON, CASPERS, VANDENBURGH,

LINDQUIST & SCHUMAN, P.A.

225 South Sixth Street, Suite 4200

Minneapolois, MN 55402

Email: gspeier@carlsoncaspers.com

Email: <a href="mailto:mschuman@carls">mschuman@carls</a>oncaspers.com

Attorneys for Teva Pharmaceuticals USA, Inc.



Michael Dzwonczyk Azadeh Kokabi Travis Ribar SUGHRUE MION, PLLC 2100 Pennsylvania Ave., NW Washington, DC 20037

Email: <u>mdzwonczyk@sughrue.com</u>

Email: <u>akokabi@sughrue.com</u>
Email: <u>tribar@sughrue.com</u>
Attorneys for Akorn Inc.

Respectfully submitted,

Dated: June 5, 2017 / Steven W. Parmelee /

Steven W. Parmelee, Lead Counsel

Reg. No. 31,990

